Cargando…
The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment
PURPOSE: To prospectively evaluate the feasibility of solid gold marker placement in oesophageal cancer patients and to quantify inter-fractional and intra-fractional (baseline shift) marker motion during radiation treatment. Radiotherapy target margins and matching strategies were investigated. MAT...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677672/ https://www.ncbi.nlm.nih.gov/pubmed/33251342 http://dx.doi.org/10.1016/j.ctro.2020.11.001 |
_version_ | 1783612022316859392 |
---|---|
author | Thomas, Melissa De Roover, Robin van der Merwe, Schalk Lambrecht, Maarten Defraene, Gilles Haustermans, Karin |
author_facet | Thomas, Melissa De Roover, Robin van der Merwe, Schalk Lambrecht, Maarten Defraene, Gilles Haustermans, Karin |
author_sort | Thomas, Melissa |
collection | PubMed |
description | PURPOSE: To prospectively evaluate the feasibility of solid gold marker placement in oesophageal cancer patients and to quantify inter-fractional and intra-fractional (baseline shift) marker motion during radiation treatment. Radiotherapy target margins and matching strategies were investigated. MATERIALS/METHODS: Thirty-four markers were implanted by echo-endoscopy in 10 patients. Patients received a planning 4D CT, daily pre-treatment cone-beam CT (CBCT) and a post-treatment CBCT for at least five fractions. For fractions with both pre- and post-treatment CBCT, marker displacement between planning CT and pre-treatment CBCT (inter-fractional) and between pre-treatment and post-treatment CBCT (intra-fractional; only for fractions without rotational treatment couch correction) were calculated in left–right (LR), cranio-caudal (CC) and anterior-posterior (AP) direction after bony-anatomy and soft-tissue matching. Systematic/random setup errors were estimated; treatment margins were calculated. RESULTS: No serious adverse events occurred. Twenty-three (67.6%) markers were visible during radiotherapy (n = 3 middle oesophagus, n = 16 distal oesophagus, n = 4 proximal stomach). Margins for inter-fractional displacement after bony-anatomy match depended on the localisation of the primary tumour and were 11.2 mm (LR), 16.4 mm (CC) and 8.2 mm (AP) for distal markers. Soft-tissue matching reduced the CC margin for these markers (16.4 mm to 10.5 mm). The mean intra-fractional shift of 12 distal markers was 0.4 mm (LR), 2.3 mm (CC) and 0.7 mm (AP). Inclusion of this shift resulted in treatment margins for distal markers of 12.8 mm (LR), 17.3 mm (CC) and 10.4 mm (AP) after bony-anatomy matching and 12.4 mm (LR), 11.4 mm (CC) and 9.7 mm (AP) after soft-tissue matching. CONCLUSION: This study demonstrated that the implantation of gold markers was safe, albeit less stable compared to other marker types. Inter-fractional motion was largest cranio-caudally for markers in the distal oesophagus, which was reduced after soft-tissue compared to bony-anatomy matching. The impact of intra-fractional baseline shifts on margin calculation was rather small. |
format | Online Article Text |
id | pubmed-7677672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-76776722020-11-27 The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment Thomas, Melissa De Roover, Robin van der Merwe, Schalk Lambrecht, Maarten Defraene, Gilles Haustermans, Karin Clin Transl Radiat Oncol Original Research Article PURPOSE: To prospectively evaluate the feasibility of solid gold marker placement in oesophageal cancer patients and to quantify inter-fractional and intra-fractional (baseline shift) marker motion during radiation treatment. Radiotherapy target margins and matching strategies were investigated. MATERIALS/METHODS: Thirty-four markers were implanted by echo-endoscopy in 10 patients. Patients received a planning 4D CT, daily pre-treatment cone-beam CT (CBCT) and a post-treatment CBCT for at least five fractions. For fractions with both pre- and post-treatment CBCT, marker displacement between planning CT and pre-treatment CBCT (inter-fractional) and between pre-treatment and post-treatment CBCT (intra-fractional; only for fractions without rotational treatment couch correction) were calculated in left–right (LR), cranio-caudal (CC) and anterior-posterior (AP) direction after bony-anatomy and soft-tissue matching. Systematic/random setup errors were estimated; treatment margins were calculated. RESULTS: No serious adverse events occurred. Twenty-three (67.6%) markers were visible during radiotherapy (n = 3 middle oesophagus, n = 16 distal oesophagus, n = 4 proximal stomach). Margins for inter-fractional displacement after bony-anatomy match depended on the localisation of the primary tumour and were 11.2 mm (LR), 16.4 mm (CC) and 8.2 mm (AP) for distal markers. Soft-tissue matching reduced the CC margin for these markers (16.4 mm to 10.5 mm). The mean intra-fractional shift of 12 distal markers was 0.4 mm (LR), 2.3 mm (CC) and 0.7 mm (AP). Inclusion of this shift resulted in treatment margins for distal markers of 12.8 mm (LR), 17.3 mm (CC) and 10.4 mm (AP) after bony-anatomy matching and 12.4 mm (LR), 11.4 mm (CC) and 9.7 mm (AP) after soft-tissue matching. CONCLUSION: This study demonstrated that the implantation of gold markers was safe, albeit less stable compared to other marker types. Inter-fractional motion was largest cranio-caudally for markers in the distal oesophagus, which was reduced after soft-tissue compared to bony-anatomy matching. The impact of intra-fractional baseline shifts on margin calculation was rather small. Elsevier 2020-11-05 /pmc/articles/PMC7677672/ /pubmed/33251342 http://dx.doi.org/10.1016/j.ctro.2020.11.001 Text en © 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Article Thomas, Melissa De Roover, Robin van der Merwe, Schalk Lambrecht, Maarten Defraene, Gilles Haustermans, Karin The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment |
title | The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment |
title_full | The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment |
title_fullStr | The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment |
title_full_unstemmed | The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment |
title_short | The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment |
title_sort | use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677672/ https://www.ncbi.nlm.nih.gov/pubmed/33251342 http://dx.doi.org/10.1016/j.ctro.2020.11.001 |
work_keys_str_mv | AT thomasmelissa theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT derooverrobin theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT vandermerweschalk theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT lambrechtmaarten theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT defraenegilles theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT haustermanskarin theuseoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT thomasmelissa useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT derooverrobin useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT vandermerweschalk useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT lambrechtmaarten useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT defraenegilles useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment AT haustermanskarin useoftumourmarkersinoesophagealcancertoquantifysetuperrorsandbaselineshiftsduringtreatment |